Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

Haejin In, Olga Kantor, Susan M. Sharpe, Marshall S. Baker, Mark S. Talamonti, Mitchell C. Posner

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Jan 11 2016

Fingerprint

Lymph Node Excision
Stomach Neoplasms
Stomach
Adenocarcinoma
Survival
Neoadjuvant Therapy
Therapeutics
Adjuvant Chemotherapy
Neoplasms
Lymph Nodes
Databases

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. / In, Haejin; Kantor, Olga; Sharpe, Susan M.; Baker, Marshall S.; Talamonti, Mark S.; Posner, Mitchell C.

In: Annals of Surgical Oncology, 11.01.2016, p. 1-7.

Research output: Contribution to journalArticle

In, Haejin ; Kantor, Olga ; Sharpe, Susan M. ; Baker, Marshall S. ; Talamonti, Mark S. ; Posner, Mitchell C. / Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. In: Annals of Surgical Oncology. 2016 ; pp. 1-7.
@article{72ee82d99f704f4a81c537d34374c63c,
title = "Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy",
abstract = "Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 {\%} received adjuvant chemoradiation; 65.4 {\%} had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.",
author = "Haejin In and Olga Kantor and Sharpe, {Susan M.} and Baker, {Marshall S.} and Talamonti, {Mark S.} and Posner, {Mitchell C.}",
year = "2016",
month = "1",
day = "11",
doi = "10.1245/s10434-015-5075-1",
language = "English (US)",
pages = "1--7",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

AU - In, Haejin

AU - Kantor, Olga

AU - Sharpe, Susan M.

AU - Baker, Marshall S.

AU - Talamonti, Mark S.

AU - Posner, Mitchell C.

PY - 2016/1/11

Y1 - 2016/1/11

N2 - Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

AB - Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84954176445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954176445&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-5075-1

DO - 10.1245/s10434-015-5075-1

M3 - Article

SP - 1

EP - 7

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -